Skip to main content

Cramer Pamela J.'s Form 4 filing

Rhythm Pharmaceuticals, Inc. (RYTM) · filed Feb 4, 2025

Accession no.
0001104659-25-009282
Filed
Feb 4, 2025
Trade date
Feb 1-4, 2025
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $53.6K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cramer Pamela J.CIK 0001873517Officer (Chief Human Resources Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 1, 2025Common StockMOption exerciseAcquired+2,650–F1–16,150Direct
Feb 4, 2025Common StockSSaleDisposed−902$59.43−$53,605.8615,248Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 1, 2025Common StockMOption exerciseDisposed−2,650$0.00$05,300Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)